Guselkumab as a Possible New Treatment for Psoriasis

Abstract

Introduction: In Mexico it affects approximately 2 million people, with a significant impact on quality of life and difficult to manage. Theoretical framework: The lesion it causes is round, salmon-pink papules and plaques, located on knees, elbows and scalp. The diagnosis is mainly clinical and the treatment will depend on the affected body surface and the location. The drugs considered first line are topical and second line drugs are used systemically, which in many occasions have adverse effects that make attachment difficult. Guselkumab, a drug approved in 2017, is an IgG1 that blocks the p19 subunit of IL-23. Discussion: Guselkumab, which is a monoclonal antibody, provides better patient outcomes compared to the drugs used in current therapeutics. There is little information currently available on Guselkumab since it has only recently been approved, but in all studies it has shown to be superior to other monoclonal antibodies, the main disadvantage being that it is not currently available in Mexico and the long administration time. Conclusion:Researching new drugs helps us to provide the patient with a treatment with the least amount of adverse effects, achieving greater adherence and better control of the disease.